Richard Kaiser was named Chief Executive Officer of Bioforce Nanosciences Holdings, Inc. As of November 6, 2026, Bioforce Nanosciences Holdings, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on June 18, 2026, naming 2 appointments (Form 8-K, June 18, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Bioforce Nanosciences Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Bioforce Nanosciences Holdings, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-06-18. It names 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Bioforce Nanosciences Holdings, Inc. files it.
Also on the record for Bioforce Nanosciences Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 4, 2026 | Stake report, Schedule 13D, by Nexus Capital Investments, Inc. | 79.6% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Bioforce Nanosciences Holdings, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Bioforce Nanosciences Holdings, Inc. and the records around it.
Bioforce Nanosciences Holdings, Inc. elsewhere on the record
- 5%+ stake filings Sep 2026
Watch Bioforce Nanosciences Holdings, Inc.
Get an email when Bioforce Nanosciences Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Bioforce Nanosciences Holdings, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Bioforce Nanosciences Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Bioforce Nanosciences Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-18 | In | 2026-06-15 | 8-K, 2026-06-18 | ||
| 2026-06-18 | In | Chief Executive Officer | 8-K, 2026-06-18 |
Who leads Bioforce Nanosciences Holdings, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Richard Kaiser, appointed (filed 2026-06-18).
New leaders reset buying decisions — get the Full Report on Bioforce Nanosciences Holdings, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Bioforce Nanosciences Holdings, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Bioforce Nanosciences Holdings, Inc.Every change, in the filing's words
Appointed: Scott Mager, effective 2026-06-15
Effective June 15, 2026, the Board of Directors appointed Scott Mager as Directors of the Company.
Appointed: Richard Kaiser, Chief Executive Officer
Officer Appointment On June 17, 2026, the Company's Board of Directors appointed Richard Kaiser as the Company's interim Chief Executive Officer.
- Resignations On June 17, 2026, the Company's Board of Directors received resignation letters from Mr. Steven Gagnon and Mr. John LaViolette as BioForce Nanosciences Holdings, Inc.'s Co-Chief Executive Officers (CEOs), and from Sasha Shapiro the Company's Vice-President.
- The Board accepted their resignations and they resigned with no conflicts of interest between the Company and the departing officers.
- Biography Scott Mager - Director Scott Mager graduated from University of Florida in 1984 and Nova Southeastern Law School in 1988.
- Mr. Mager brings a wealth of legal, regulatory, and strategic expertise to the Board, serving as a renowned corporate attorney and seasoned trial lawyer licensed across multiple states and the United States Supreme Court.
- Recognized globally for his professional excellence, he has been named National Litigator of the Year by a prominent multi-billion-dollar corporate conglomerate and holds the highest peer-reviewed rating for both ethical standards and professional ability from the world's leading attorney rating organization.
- A prolific thought leader, Mr. Mager, has over 150 published articles and lectures on complex legal and business issues.
- Beyond his legal practice, he has partnered across a variety of successful business and entrepreneurial endeavors, offering vital governance and strategic oversight.
Tools for this story
Each opens in a new tab, filled in for Bioforce Nanosciences Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.